BACKGROUND: High-intensity focused ultrasound (HIFU) is a non-invasive method of solid tissue ablation therapy. However, only a few studies have reported the effect of HIFU for unresectable pancreatic cancer. This study aimed to evaluate the clinical benefits, survival time and complications associated with the use of HIFU ablation in patients with unresectable pancreatic cancer. METHODS: Twenty-five patients with unresectable pancreatic cancer were enrolled in our study. All patients received HIFU therapy for tumors at least once. The therapeutic effects of HIFU was evaluated in terms of Karnofsky performance status (KPS) scores, pain relief, serum CA19-9, and imaging by B-US and CT before and after the therapy. We also recorded median overall survival time and complications caused by the treatment. RESULTS: In the 25 patients, KPS scores were above 60, and increased KPS was observed in 23 patients after treatment. Pain relief occurred in 23 patients. Serum CA19-9 levels were significantly reduced one month after HIFU treatment and became negative in 5 patients. B-US revealed enhanced tumor echogenicity in 13 patients and decreased tumor blood supply in 9. Tumor necrosis was confirmed by CT in 8 patients one month after HIFU treatment. The median overall survival time was 10 months, and the 1-year survival rate was 42%. No severe complications were observed after HIFU treatment. CONCLUSION: HIFU can effectively relieve pain, increase KPS, decrease tumor growth and prolong the survival time of patients with unresectable pancreatic cancer.
BACKGROUND: High-intensity focused ultrasound (HIFU) is a non-invasive method of solid tissue ablation therapy. However, only a few studies have reported the effect of HIFU for unresectable pancreatic cancer. This study aimed to evaluate the clinical benefits, survival time and complications associated with the use of HIFU ablation in patients with unresectable pancreatic cancer. METHODS: Twenty-five patients with unresectable pancreatic cancer were enrolled in our study. All patients received HIFU therapy for tumors at least once. The therapeutic effects of HIFU was evaluated in terms of Karnofsky performance status (KPS) scores, pain relief, serum CA19-9, and imaging by B-US and CT before and after the therapy. We also recorded median overall survival time and complications caused by the treatment. RESULTS: In the 25 patients, KPS scores were above 60, and increased KPS was observed in 23 patients after treatment. Pain relief occurred in 23 patients. Serum CA19-9 levels were significantly reduced one month after HIFU treatment and became negative in 5 patients. B-US revealed enhanced tumor echogenicity in 13 patients and decreased tumor blood supply in 9. Tumor necrosis was confirmed by CT in 8 patients one month after HIFU treatment. The median overall survival time was 10 months, and the 1-year survival rate was 42%. No severe complications were observed after HIFU treatment. CONCLUSION: HIFU can effectively relieve pain, increase KPS, decrease tumor growth and prolong the survival time of patients with unresectable pancreatic cancer.
Authors: Dobromir Dimitrov; Holger M Strunk; Milka Marinova; Hyuliya Feradova; Maria A Gonzalez-Carmona; Rupert Conrad; Tolga Tonguc; Marcus Thudium; Marc U Becher; Zhou Kun; Grigor Gorchev; Slavcho Tomov; Christian P Strassburg; Ulrike Attenberger; Hans H Schild Journal: Eur Radiol Date: 2021-01-23 Impact factor: 5.315
Authors: M Marinova; H M Strunk; M Rauch; J Henseler; T Clarens; L Brüx; R Dolscheid-Pommerich; R Conrad; H Cuhls; L Radbruch; H H Schild; M Mücke Journal: Schmerz Date: 2017-02 Impact factor: 1.107
Authors: Margaret G Keane; Konstantinos Bramis; Stephen P Pereira; Giuseppe K Fusai Journal: World J Gastroenterol Date: 2014-03-07 Impact factor: 5.742
Authors: Milka Marinova; Maximilian Rauch; Martin Mücke; Roman Rolke; Maria A Gonzalez-Carmona; Jana Henseler; Henning Cuhls; Lukas Radbruch; Christian P Strassburg; Lian Zhang; Hans H Schild; Holger M Strunk Journal: Eur Radiol Date: 2016-02-17 Impact factor: 5.315
Authors: Ezekiel Maloney; Tanya Khokhlova; Venu G Pillarisetty; George R Schade; Elizabeth A Repasky; Yak-Nam Wang; Lorenzo Giuliani; Matteo Primavera; Joo Ha Hwang Journal: Int Rev Immunol Date: 2017-09-29 Impact factor: 5.311